Compare CCL & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCL | PODD |
|---|---|---|
| Founded | 1972 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2B | 22.1B |
| IPO Year | 1987 | 2007 |
| Metric | CCL | PODD |
|---|---|---|
| Price | $27.75 | $295.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 19 |
| Target Price | $34.24 | ★ $359.00 |
| AVG Volume (30 Days) | ★ 19.0M | 791.4K |
| Earning Date | 12-19-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.65 | N/A |
| EPS | 1.94 | ★ 3.45 |
| Revenue | ★ $26,230,000,000.00 | $2,521,800,000.00 |
| Revenue This Year | $7.63 | $32.55 |
| Revenue Next Year | $4.33 | $20.39 |
| P/E Ratio | ★ $14.25 | $85.69 |
| Revenue Growth | 7.15 | ★ 27.11 |
| 52 Week Low | $15.07 | $230.05 |
| 52 Week High | $32.80 | $354.88 |
| Indicator | CCL | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 57.80 | 38.33 |
| Support Level | $25.27 | $290.98 |
| Resistance Level | $26.15 | $306.04 |
| Average True Range (ATR) | 0.87 | 9.59 |
| MACD | 0.32 | -3.01 |
| Stochastic Oscillator | 85.61 | 9.03 |
Carnival is the largest global cruise company, with more than 90 ships in service. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It recently folded its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted 14 million guests in 2024.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.